Adverse events were less frequent with dapagliflozin than placebo (56% vs 64%), and no serious adverse events were reported in the dapagliflozin group [32]
The authors would also like to thank SYSBIO/ISBE.IT Center of Systems Biology, particularly Professor Lilia Alberghina, and the Project of Excellence CHRONOS (CHRonical multifactorial disorders explored by NOvel integrated Strategies) of the Department of Biotechnology and Biosciences, University of Milano-Bicocca, for providing advanced technologies used in this study
This is important considering the shared risk factors, particularly elevated blood pressure, dyslipidaemia and obesity, for developing CVD and T2DM
The efficacy gap is enormous
fill-finish & sterile handling Lyophilized for long-term stability Tamper-evident vial What is BPC-157: BPC-157 is a synthetic peptide studied for how it interacts with cellular signaling involved in tissue repair and inflammation pathways